World Investment Advisors LLC Buys Shares of 1,097 United Therapeutics Co. (NASDAQ:UTHR)

World Investment Advisors LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,097 shares of the biotechnology company’s stock, valued at approximately $393,000.

A number of other hedge funds have also modified their holdings of UTHR. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. FMR LLC increased its stake in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Assetmark Inc. increased its stake in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of United Therapeutics by 49.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock worth $88,089,000 after purchasing an additional 91,597 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of United Therapeutics stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now owns 5,783 shares in the company, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the transaction, the director now owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on UTHR shares. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Argus lifted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Stock Up 1.8 %

Shares of UTHR opened at $379.69 on Wednesday. The firm has a market cap of $16.95 billion, a PE ratio of 16.68, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54. The company’s fifty day moving average is $370.88 and its two-hundred day moving average is $344.17. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.38 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.